| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23016 |
| Drug |
Ivosidenib |
| Brand |
Tibsovo® |
| Indication |
For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy |
| Rapid review commissioned |
08/03/2023 |
| Rapid review completed |
17/04/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/06/2023 |
| Pre-submission consultation with Applicant |
05/09/2023 |
| Full submission received from Applicant |
16/02/2024 |
| Preliminary review sent to Applicant |
01/11/2024 |
| NCPE assessment re-commenced |
29/11/2024 |
| Follow-up to preliminary review sent to Applicant |
11/12/2024 |
| NCPE assessment re-commenced |
17/12/2024 |
